Usefulness of the Parent Compound Determination in Bioequivalence Evaluation of Clopidogrel Generic Products

Abstract

Objective:

The aim of the presented comparative study was to evaluate the bioavailability of clopidogrel (CAS 113665-84-2) formulations containing clopidogrel bisulfate (CAS 135046-48-9, CBS) 75 mg based on the parent compound (CBS) and its metabolite SR 26334 –clopidogrel carboxylic acid (CAS 144457-28-3, CCA) determination.

Methods:

This paper presents the results of a comparative, randomized, two-way cross-over study on 48 healthy male volunteers assessing the bioequivalence of two products of clopidogrel 75mg in form of film-coated tablets. In each of the two periods, separated by a 7-day washout period, a single dose of 150 mg (2 2 75mg) of test and reference preparations was administered under fasting condition. Nineteen blood samples for determination of CBS and CCA were collected up to 48 h post dose. The CBS and CCA concentrations were quantified by a selective ultra performance liquid chromatographic-tandem mass spectrometric (UPLC-MS/MS) method.

Pharmacokinetic parameters such as AUC_inf, AUC_t, C_max, t _max, t _1/2 were estimated using a non-compartmental model. Bioequivalence evaluation and calculation of CI were performed for clopidogrel and its metabolite by two one-sided t-test procedures by Schuirmann.

Results:

In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUC_inf: 15 773 vs. 15 691 ng · h/mL, AUC_t : 15 462 vs. 15 315 ng · h/mL, C _max : 4919 vs. 4699 ng/mL, t _max : 0.84 vs. 0.93 h, t _1/2: 7.92 vs. 8.41 h. Points of estimation of the ratios test/reference were near to 100% and CI in ranges 80–125% were fulfilled for all tested parameters.

Pharmacokinetic parameters values of CBS were: AUC_inf : 1.96 vs. 1.84 ng · h/mL (test vs reference), AUC_t : 1.91 vs. 1.81 ng · h/mL, C _max 1.44 vs. 1.52 ng/mL, t _max : 0.90 vs. 0.99 h, t_1/2: 0.74 vs. 0.57 h. The parametric 90%-confidence interval (CI) was in the range of 80–125% for AUC_t ratio and AUC_inf ratio. The CI range of C _max fulfilled the widened range of 75–133 % (according to the study protocol). Unfortunately, the very high variability of pharmacokinetic parameters (over 50%) contributed to low power of the test.

Conclusions:

Measurement of CBS concentrations should not be a reliable one for the bioequivalence assessment, due to very low concentrations, very small and variable values of AUC and high intra-subject variability. Thus, bioequivalence evaluation should be based on CCA determination. In the presented study evaluation based on CCA unequivocally and with the proper power confirmed the bioequivalence between the investigated clopidogrel products.

Key words

Areplex® - CAS 113665-84-2 - CAS 144457-28-3 - clopidogrel - clopidogrel carboxylic acid, bioequivalence, pharmacokinetics, UPLC-MS/MS - Platelet aggregation inhibitors

• References

• 1 Jarvis B, Simpson K. Clopidogrel, a review of its use in the prevention of atherothrombosis. Drugs. 2000; 60 (2) 347-77
• 2 Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin. Throm. Homeost. 1999; 25 (2) 25-8
• 3 Lagorce P, Perez Y, Ortiz J, Necciari J, Bressolle F. Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl. 1998; 11: 720 (1–2) 107-17
• 4 McEwen J, Strauch G, Perlrs P, Pritchard G, Moreland TE, Necciari J et al Clopidogrel bioavailability: absence of influence of food or antacids. Semin. Thromb. Hemost. 1999; 25 (2) 47-50
• 5 Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20 (11) 1695-1700
• 6 Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. Jss. Pharm. Biom. Anal. 2006; 41: 533-9
• 7 Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Shekarchi M, Dalvandi A. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chrmatogr. 2006; 20 (12) 1309-14
• 8 Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004; 54 (9 a) 600-4
• 9 Nirogi RV, Kandikere VN, Mudigonda K. Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. Arzneimittelforschung. 2006; 56 (11) 735-9
• 10 Shin BS, Yoo SD. Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetics study. Biomed Chromatogr. 2007; 21 (9) 883-9
• 11 CPMP/EWP/QWP/1401/98, Note for guidance on the investigation of bioavailability and bioequivalence; 2001
• 12 EMEA/CHMP/EWP/40326/2006, Questions and Answers on the Bioavailability and Bioequivalence Guideline; 2006
• 13 CPMP/ICH/363/96, Note for Guidance on statistical principles for clinical trials; 1998
• 14 Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol. 2000; 40: 396-401
• 15 Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P et al Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002; 30 (11) 1288-95